Leukotriene Receptor Antagonists Inhibit Mitogenic Activity in Triple Negative Breast Cancer Cells

Area of Science:

• Oncology
• Pharmacology

Background:

• Hormonal pathways are key in breast cancer, but alternative, hormone-independent targets are needed for a cure.
• Cysteinyl leukotriene receptor antagonists (LTRAs) are known for treating inflammatory diseases and have shown promise in reducing lung cancer risk and inhibiting tumor progression in other cancers.

Purpose of the Study:

• To evaluate the effects of two clinically relevant LTRAs, montelukast and zafirlukast, on a triple-negative breast cancer cell line (MDAMB-231).
• To investigate the potential of LTRAs as a hormone-independent therapeutic strategy for breast cancer.

Main Methods:

• The study utilized the MDAMB-231 triple-negative breast cancer cell line.
• Cells were treated with varying doses of montelukast and zafirlukast to determine their effects on cell viability, apoptosis, and cell cycle progression.

Main Results:

• Both montelukast and zafirlukast significantly reduced breast cancer cell viability in a dose-dependent manner, with an IC50 between 5-10 μM.
• Montelukast primarily induced apoptosis, while zafirlukast predominantly affected the cell cycle.
• The specific mechanisms behind these differential effects require further investigation.

Conclusions:

• Cysteinyl leukotriene (CysLT) signaling appears to play a role in the proliferation and survival of breast cancer cells, even in the absence of hormonal stimulation.
• LTRAs represent a potential therapeutic avenue for hormone-independent breast cancers, warranting further research into their mechanisms of action.